S. Dierckx
YOU?
Author Swipe
View article: Evolution from early to difficult-to-treat rheumatoid arthritis: incidence and risk factors in the ERA uclouvain Brussels cohort
Evolution from early to difficult-to-treat rheumatoid arthritis: incidence and risk factors in the ERA uclouvain Brussels cohort Open
View article: Lung involvement in rheumatoid arthritis, a prospective study
Lung involvement in rheumatoid arthritis, a prospective study Open
Background The prevalence of lung involvement in rheumatoid arthritis (RA) remains elusive. Therefore, we set up a multicentric prospective study to investigate the presence of interstitial lung disease (ILD), emphysema, bronchiolitis and …
View article: The clinical implications of using a low threshold for computed tomography scans in older patients presenting with a proximal femur fracture
The clinical implications of using a low threshold for computed tomography scans in older patients presenting with a proximal femur fracture Open
View article: Dramatic response of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome to tofacitinib monotherapy: a case report
Dramatic response of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome to tofacitinib monotherapy: a case report Open
View article: Trajectory Evolution from Early to Difficult-to-Treat Rheumatoid Arthritis: Incidence and Associated Risk Factors in the Early Rheumatoid Arthritis Uclouvain Brussels Cohort
Trajectory Evolution from Early to Difficult-to-Treat Rheumatoid Arthritis: Incidence and Associated Risk Factors in the Early Rheumatoid Arthritis Uclouvain Brussels Cohort Open
View article: AB0955 WITHDRAWAL FROM PROFESSIONAL LIFE DUE TO HIGH DISEASE ACTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH TUMOUR NECROSIS FACTOR INHIBITORS AND/OR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN ROUTINE CARE: RESULTS FROM THE MULTINATIONAL “INVISIBLE” STUDY
AB0955 WITHDRAWAL FROM PROFESSIONAL LIFE DUE TO HIGH DISEASE ACTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH TUMOUR NECROSIS FACTOR INHIBITORS AND/OR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN ROUTINE CARE: RESULTS FROM THE MULTINATIONAL “INVISIBLE” STUDY Open
View article: Should We Use bDMARDs as an Induction Therapy in Early and Severe Rheumatoid Arthritis? Results at 5 years from the ERA UCLouvain Brussels Cohort
Should We Use bDMARDs as an Induction Therapy in Early and Severe Rheumatoid Arthritis? Results at 5 years from the ERA UCLouvain Brussels Cohort Open
Long-term remission is an achievable goal in ERA. Our results suggest that a bDMARD induction therapy followed by MTX maintenance therapy could be an interesting option.
View article: Editorial: Risk factors for Rheumatoid Arthritis and pre-Rheumatoid Arthritis
Editorial: Risk factors for Rheumatoid Arthritis and pre-Rheumatoid Arthritis Open
This Research Topic, entitled Risk factors for Rheumatoid Arthritis and pre-Rheumatoid Arthritis, is focused on understanding the myriad of etiological factors implied in the pathophysiology of RA, identifying possible preconditions of RA,…
View article: COVID-19 dans ma clinique de PR : données du questionnaire, de la vaccination, de l’infection et des poussées de la polyarthrite dans la cohorte PR Louvain Brussels
COVID-19 dans ma clinique de PR : données du questionnaire, de la vaccination, de l’infection et des poussées de la polyarthrite dans la cohorte PR Louvain Brussels Open
View article: Anti-TNF Induced Sarcoidosis-Like Disease in Rheumatoid Arthritis Patients: Review Cases from the RA UCLouvain Brussels Cohort
Anti-TNF Induced Sarcoidosis-Like Disease in Rheumatoid Arthritis Patients: Review Cases from the RA UCLouvain Brussels Cohort Open
View article: Acceptation de la vaccination contre la Covid-19 par les patients PR ? Résultats de la cohorte PR Louvain Bruxelles
Acceptation de la vaccination contre la Covid-19 par les patients PR ? Résultats de la cohorte PR Louvain Bruxelles Open
View article: POS1196 COVID-19 VACCINE WILLINGNESS IN RA? RESULTS FROM THE RA LOUVAIN BRUSSELS COHORT
POS1196 COVID-19 VACCINE WILLINGNESS IN RA? RESULTS FROM THE RA LOUVAIN BRUSSELS COHORT Open
View article: Validation of Coronary Angiography-Derived Vessel Fractional Flow in Heart Transplant Patients with Suspected Graft Vasculopathy
Validation of Coronary Angiography-Derived Vessel Fractional Flow in Heart Transplant Patients with Suspected Graft Vasculopathy Open
View article: Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort
Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort Open
Objectives To evaluate the proportion of patients with early RA (ERA) who had or had not initiated glucocorticoids, to analyse the baseline characteristics, and to assess the clinical benefit and side effects of glucocorticoids during 5 ye…
View article: FRI0021 SHOULD WE USE GLUCOCORTICOID IN EARLY RHEUMATOID ARTHRITIS?: RESULTS AT 5 YEARS FROM THE ERA LOUVAIN BRUSSELS COHORT
FRI0021 SHOULD WE USE GLUCOCORTICOID IN EARLY RHEUMATOID ARTHRITIS?: RESULTS AT 5 YEARS FROM THE ERA LOUVAIN BRUSSELS COHORT Open
View article: Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort
Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort Open
View article: SAT0076 EARLY REMISSION IS ESSENTIAL TO PREDICT LONGTERM REMISSION. CLINICAL RESULTS OF THE BELGIAN CAP48 RA COHORT
SAT0076 EARLY REMISSION IS ESSENTIAL TO PREDICT LONGTERM REMISSION. CLINICAL RESULTS OF THE BELGIAN CAP48 RA COHORT Open
View article: FRI0085 TAPERING OF BIOLOGICAL ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS PATIENTSIS ACHIEVABLE AND COST EFFECTIVE IN DAILY CLINICAL PRACTICE: DATA FROM THE BRUSSELS UCL RA COHORT
FRI0085 TAPERING OF BIOLOGICAL ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS PATIENTSIS ACHIEVABLE AND COST EFFECTIVE IN DAILY CLINICAL PRACTICE: DATA FROM THE BRUSSELS UCL RA COHORT Open